Format

Send to

Choose Destination
Vaccine. 2013 Dec 17;32(1):124-30. doi: 10.1016/j.vaccine.2013.03.063. Epub 2013 Apr 12.

Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB).

Author information

1
Vaccine Evaluation Center, BC Children's Hospital and the University of British Columbia, Vancouver V5Z4H4, Canada. Electronic address: jbettinger@cfri.ca.
2
Vaccine Evaluation Center, BC Children's Hospital and the University of British Columbia, Vancouver V5Z4H4, Canada.
3
Canadian Center for Vaccinology, IWK Health Centre and Dalhousie University, Halifax B3K6R8, Canada.
4
Stollery Children's Hospital and University of Alberta, Edmonton T6G1C9, Canada.
5
Vaccine Evaluation Unit, Health Protection Agency, Manchester M13 9WZ, UK.
6
Novartis Vaccines, Siena 53100, Italy.
7
National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg R3E3R2, Canada.

Abstract

BACKGROUND:

In collaboration with the Canadian Immunization Monitoring Program Active (IMPACT), the National Microbiology Laboratory, the UK Health Protection Agency and Novartis Vaccines, we tested the potential of an investigational 4-component meningococcal B vaccine (4CMenB) to cover Canadian strains circulating from 2006 to 2009.

METHODS:

IMPACT meningococcal surveillance is population based and includes over 50% of Canadian adults and children. All isolates were characterized by Meningococcal Antigen Typing System (MATS) and sequencing for factor H-binding protein (fHbp), Neisseria Heparin Binding Antigen (NHBA) and Neisserial adhesin A (NadA).

RESULTS:

In total, 157 isolates were tested. Overall, 4CMenB MATS predicted strain coverage was 66% (95% CI: 46-78%), with 26%, 29% and 11% of strains covered by one, two and three vaccine antigens, respectively. The coverage of each antigen was as follows: 13% PorA, 1% NadA, 52% fHbp and 51% NHBA. The majority of strains for clonal complex (cc) 41/44 and cc60 were covered by NHBA; the majority of strains for cc269 and cc32 were covered by fHbp and NHBA. Coverage for two prevalent strains (sequence type (ST)-269 and ST-154) was 95% and 100%, respectively.

CONCLUSIONS:

4CMenB has the potential to protect against a significant proportion of Canadian invasive MenB strains.

KEYWORDS:

4CMenB coverage; Invasive meningococcal disease; Meningitis; Meningococcal Antigen Typing System; Serogroup B vaccines

PMID:
23588089
DOI:
10.1016/j.vaccine.2013.03.063
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center